Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 142-150

  Majhail, Navneet S ^a,b   Chitphakdithai, Pintip ^b   Logan, Brent ^c   King, Roberta ^b   Devine, Steven ^d   Rossmann, Susan N ^e   Hale, Gregory ^f   Hartzman, Robert J ^g   Karanes, Chatchada ^h   Laport, Ginna G ⁱ   Nemecek, Eneida ^j   Snyder, Edward L ^k   Switzer, Galen E ^l   Miller, John ^b   Navarro, Willis ^b   Confer, Dennis L ^b   Levine, John E ^m  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^g NAVAL MEDICAL RESEARCH CENTER   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

Hematopoietic cell transplantation; National Marrow Donor Program; Survival; Treatment related mortality; Unrelated donors

Indexed keywords

ADULT; ARTICLE; BONE MARROW; CELL SURVIVAL; DONOR SELECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT SELECTION; UNRELATED DONORS; ADOLESCENT; AGED; ALLOTRANSPLANTATION; CHILD; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL ANALYSIS; TIME FACTOR; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927152756     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.001     Document Type: Article

References (24)

1. Karanes C., Nelson G.O., Chitphakdithai P., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:8-15.
2. MacMillan M.L., Davies S.M., Nelson G.O., et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:16-22.
3. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. JClin Oncol 2013, 31:2437-2449.
4. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2013, Available at:. http://www.cibmtr.org.
5. Schetelig J., Bornhauser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. JClin Oncol 2008, 26:5183-5191.
6. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116:1839-1848.
7. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. JClin Oncol 2006, 24:5695-5702.
8. Moore J., Nivison-Smith I., Goh K., et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007, 13:601-607.
9. Eapen M., Rubinstein P., Zhang M.J., et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. JClin Oncol 2006, 24:145-151.
10. Walter R.B., Pagel J.M., Gooley T.A., et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010, 24:1276-1282.
11. Majhail N.S., Omondi N.A., Denzen E., et al. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2010, 16:1070-1075.
12. Pidala J., Craig B.M., Lee S.J., et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2013, 48:63-67.
13. Majhail N.S., Murphy E.A., Omondi N.A., et al. Allogeneic transplant physician and center capacity in the United States. Biol Blood Marrow Transplant 2011, 17:956-961.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
15. Klein J.P., Moeschberger M.L. Survival analysis: techniques for censored and truncated data 2003, Springer Verlag, New York. 2nd ed.
16. Cox D.R. Regression models and life tables. JR Stat Soc 1972, 34:187-202.
17. Wingard J.R., Majhail N.S., Brazauskas R., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. JClin Oncol 2011, 29:2230-2239.
18. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
19. Horan J.T., Logan B.R., Agovi-Johnson M.A., et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. JClin Oncol 2011, 29:805-813.
20. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
21. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. JClin Oncol 2010, 28:1878-1887.
22. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. JClin Oncol 2010, 28:405-411.
23. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
24. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.